"Illustration of Dupixent Treatment"
Drug Updates

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the […]

Drug Updates

Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of Kadmon Holdings, Inc.

Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced it signed a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ: KDMN), a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core […]